



CIN NO.: L24230WB1982PLC034492

30th May, 2018

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

To,
Dy. General Manager,
Corporate Relationship Department,
BSE Limited,
P. J. Tower,
Mumbai – 400 001

SUB: Submission of Audited Financial Results for the 04th Quarter and year ended 31st March, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of Board of Directors of the Company held at its Registered Office on Wednesday, 30th May, 2018 (which commenced at 11.00 A.M. and concluded 12.50 P.M.) wherein they have adopted / approved:

- 1) The Audited Standalone Financial Results of the Company for the 4th quarter and Year ended 31/03/2018 along with the Statement of Assets and Liabilities.
- 2) Statement on Impact of Audit Qualifications (for Audit Report with unmodified opinion)
- 3) Auditor's Report on the Annual Audited Standalone Financial Results.
- 4) Declaration by Whole-time Director pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulation, 2016.
- 5) M/s. S. R. Ghedia & Associates, Chartered Accountants, Mumbai has resigned from the post of Internal Auditor of the Company for the Financial Year 2017-18.
- 6) Appointment of M/s M. H. Parihar & Co., Chartered Accountants as Internal Auditors of the Company for Financial Year 2017-2018 pursuant to Section 138 of the Companies Act, 2013.



Email: investors@adinathbio.com
<http://www.adinathbio.com>

4, N. S. Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718

The said results will be duly published in the newspapers within due course of time.

The above information is also available on Company's website www.adinathbio.com and on the Stock exchange website: www.bseindia.com and www.cse-india.com.

Request you to kindly take the above on record.

Thanking you,


Yours faithfully,
For Adinath Bio- Labs Limited



Kishan Singh
Whole-Time Director
DIN: 07526266
Encl.: As above



Statement of Standalone Audited Financial Results for the quarter and year ended 31st March, 2018						
PART I					Amount (In Rs.)	
Sl. No.	Particulars	Quarter Ended			Year Ended	
		Audited	Unaudited	Audited	Audited	Audited
		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
1	Income from operations					
	(a) Net Sales / income from operations	-	-	9,66,800	4,68,461	55,81,586
	(b) Other Income	41,30,469	1,60,000	79,367	49,10,573	79,367
	Total income from operations (net)	41,30,469	1,60,000	10,46,167	53,79,034	56,60,953
2	Expenses					
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	70,38,265	-	-	70,38,265	-
	(b) Employee benefits expense	60,000	2,50,431	3,37,460	10,63,835	22,27,355
	(c) Finance Cost	-	-	-	-	-
	(d) Depreciation and amortisation expense	2,15,041	2,15,093	2,86,195	8,56,166	11,44,780
	(e) Other expenses	55,23,993	1,86,326	3,37,599	62,64,067	19,31,413
	Total expenses	1,28,37,299	6,51,850	9,61,254	1,52,22,333	53,03,548
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(87,06,830)	(4,91,850)	84,913	(98,43,299)	3,57,405
4	Exceptional & Extraordinary Items	1,86,56,065	3,45,00,000	-	5,31,56,065	-
5	Profit / (Loss) before Tax (3 + 4)	(2,73,62,895)	(3,49,91,850)	84,913	(6,29,99,364)	3,57,405
6	Tax expense					
	Current Tax	-	-	-	-	98,000
	Deferred Tax	-	-	-	20,693	9,585
	Earlier Years	-	-	-	73,01,817	-
	Total Tax Expenses	-	-	-	73,22,510	1,07,585
7	Net Profit / (Loss) after tax (5 + 6)	(2,73,62,895)	(3,49,91,850)	84,913	(7,03,21,874)	2,49,820
8	Other Comprehensive Income / (Loss)	-	-	-	-	-
9	Total Comprehensive Income / (Loss) (7 + 8)	(2,73,62,895)	(3,49,91,850)	84,913	(7,03,21,874)	2,49,820
10	Paid-up equity share capital (Face Value of the Share shall be indicated)(%)	22,07,42,560 1	22,07,42,560 1	22,07,42,560 1	22,07,42,560 1	22,07,42,560 1
11	Earnings Per Share (not annualised):					
	Basic & Diluted	(0.12)	(0.16)	0.00	(0.32)	0.00




Statement of Audited Assets and Liabilities as on 31st March, 2018

Sl. No.	Particulars	As at 31st March, 2018	As at 31st March, 2017
I	ASSETS		
A	Non-current assets		
	a) Property, plant and equipment	26,04,105	44,19,117
	b) Capital work-in-progress	-	1,86,56,065
	c) Intangible assets		
	d) Financial assets		
	i) Investments	3,25,003	53,87,499
	ii) Other Non current financial assets	8,02,32,694	11,11,77,694
	Total Non-current assets	8,31,61,802	13,96,40,375
B	Current assets		
	a) Inventories	-	70,38,265
	b) Financial assets		
	i) Trade receivable	62,04,269	62,04,269
	ii) Cash and cash equivalents	93,325	2,63,814
	iii) Loans and Advances	25,20,000	25,30,000
	iv) Other current financial assets	34,79,360	25,17,000
	c) Other current assets	-	-
	Total Current assets	1,22,96,954	1,85,53,348
	TOTAL ASSETS	9,54,58,756	15,81,93,723
II	EQUITY AND LIABILITIES		
A	EQUITY		
	a) Equity Share capital	22,07,42,560	22,07,42,560
	b) Other Equity	(13,46,82,347)	(6,43,60,473)
	Total equity	8,60,60,213	15,63,82,087
B	LIABILITIES		
I	Non-current liabilities		
	a) Financial liabilities		
	i) Borrowings	-	-
	ii) Other non-current financial liabilities	-	-
	(b) Long term provisions	-	-
	(c) Deferred tax liabilities (net)	1,76,016	1,55,323
	Total Non-current liabilities	1,76,016	1,55,323
II	Current liabilities		
	a) Financial liabilities		
	i) Borrowings	-	-
	ii) Trade payables	-	-
	iii) Other current financial liabilities	-	-
	b) Other current liabilities	7,75,212	3,28,235
	c) Provisions	-	64,000
	d) Current tax liabilities	84,47,315	12,64,078
	Total Current liabilities	92,22,527	16,56,313
	TOTAL EQUITY AND LIABILITIES	9,54,58,756	15,81,93,723

Date: 30th May, 2018
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited



Kishan Singh
Whole - Time Director
DIN No.: 07526266

Notes:

- The above Audited Financial results have been reviewed by the Audit Committee at their meeting held on 30th May, 2018 and adopted by the Board of Directors at their meeting held on 30th May, 2018.
- The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Beginning with 01st April, 2017, the Company has for the first time adopted Ind AS with the transition date of 01st April, 2016. The financial results are made available on the company's website www.adinathbio.com. Financial Results of all the periods presented have been prepared in accordance with the recognition and the measurement principles of IND AS - 34 (Interim Financial Reporting).
- The Company is engaged in the business of Trading in Commodities and its allied products and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The figures of the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between the audited figures of the following financial year ended March 31, 2018 and March 31, 2017 and the published year to date figures upto nine months ended December 31, 2017 and December 31, 2016 respectively.
- Provisions for taxations is made on the taxable income for the full year in accordance with the provisions of Income Tax Act, 1961.
- Capital Work-in-progress have been written off during the current period.
- Reconciliation of Profit, as previously reported under IGAAP to Ind-AS for the quarter and year ended on 31st March 2017 is given below:

Particulars	Corresponding 3 months ended in the previous year March 31, 2017	Corresponding year ended on March 31, 2017
Net Profit/ (Loss) for the quarter under previous Indian GAAP	23,546	2,07,298
Add/ (Less): Adjustments with respect to Ind AS compliance	61,367	42,522
Net Profit/ (Loss) for the quarter under IND AS	84,913	2,49,820

- Reconciliation of other equity, as previously reported under IGAAP to Ind-AS for the year ended on 31st March 2017 is given below:

Particulars	As at March 31, 2017
Equity as per Previous GAAP (Indian GAAP)	29,32,11,442
Add/ (Less): Adjustments with respect to Ind AS compliance	
Fair Valuation of Financial Instruments	(19,42,701)
Fair Valuation of Financial Assets	(13,48,67,808)
Deferred Tax on Ind AS Adjustments	(18,945)
Equity as reported under Ind AS	15,63,82,088

The reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 05, 2016 on account of implementation of Ind-AS by listed companies.

- Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

Date: 30th May, 2018
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited


Kishan Singh
Kishan Singh
Whole-Time Director
DIN No.: 07526266

**“Statement on Impact of Audit Qualifications”
(For Audit Report with unmodified opinion)**

**As per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

1.	Name of the company	Adinath Bio-Labs Limited
2.	Annual financial statements for the year ended	31 st March 2018 (Standalone)
3.	Type of Audit observation	Un Modified
4.	Frequency of observation	Not Applicable

For Adinath Bio- Labs Limited



Kishan Singh
Whole-Time Director
DIN: 07526266




**For Mohindra Arora & Co.
(Chartered Accountants)**



Ashok Kumar Katial
Partner
M. No. 09096




For Adinath Bio- Labs Limited



Ganga Sahai
Director
DIN: 07116838



For Adinath Bio- Labs Limited



Shri Prakash
Audit Committee Chairman
DIN: 07526354



Independent Auditor's Report on Quarterly Standalone Financial Results and Standalone year to date Results of Adinath Biolabs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Adinath Biolabs Limited

We have audited the standalone financial results ('the Statement') of Adinath Biolabs Limited for the quarter and year ended March 31, 2018 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended March 31, 2018 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the current and previous financial year respectively Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

The Statement has been prepared on the basis of annual audited financial statements and reviewed quarterly financial results upto the end of third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements, which have been prepared by the management in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with rules issued there under, other accounting principles generally accepted in India and in compliance with requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We conducted our review in accordance with the Auditing Standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement. An audit includes examining, on a test basis, evidence supporting amounts disclosed in the statement. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

The financial results for the quarter and year ended March 31, 2017 reported under previous GAAP, included in the Statement are based on the previously issued results of the Company, prepared in accordance with the Accounting Standards as per Section 133 of the Act 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014. These results were audited by previous auditor and their report dated May 25, 2017 expressed an unmodified opinion. Management has adjusted these results for the differences in the accounting principles adopted by the Company on transition to the Indian Accounting Standards (Ind AS) and presented reconciliation for the same, which has been approved by the Company's Board of Directors and audited by us.



In our opinion and to the best of our information and according to the explanations given to us the Statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular dated July 5, 2016 in this regard; and
- b. give a true and fair View of the financial performance including other comprehensive income and other financial information for the quarter ended March 31, 2018 and for the year ended March 31, 2018.

For, Mohindra Arora & Co.
Chartered Accountants
Firm registration No: 006551N



Ashok Kumar Katial
Partner
Membership No: 09096

Place : Mumbai
Date : May 30, 2018

DECLARATION

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016

Dear Sir,


I, Kishan Singh (DIN: 07526266) Whole Time Director of Adinath Bio-Labs Limited, hereby declared and confirmed that, the Statutory Auditors of the Company, M/s. Mohindra Arora & Co., Chartered Accountants (FRN: 00655IN) have issued an Audit Report with unmodified opinion on Annual Audited Standalone Financial Results for the quarter and year ended 31st March, 2018.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25/05/2016 and Circular No. CIR/CFD/CMD/56/2016 dated 27/05/2016.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited



Kishan Singh
(Whole-Time Director)
DIN: 007526266



Date: 30/05/2018

Place: Kolkata